a. lipoprotein lipase
b. hepatic lipase
c. cholesterol ester transport protein
d. all of the above

2. The condition of relatively high levels of small LDL particles is referred to as “phenotype B.” This state can be induced by:

a. high dietary carbohydrate intake and obesity
b. high dietary fat intake and obesity
c. high dietary fat and carbohydrate intake
d. obesity alone

3. Increasing dietary fat will increase levels of HDL cholesterol:

a. In normal weight persons
b. With certain polymorphisms of the hepatic lipase promoter gene, while those with other polymorphisms show lowering of HDL cholesterol with increased fat intake
c. In persons with diabetes
d. In persons with obesity, with BMI > 30 kg/m2 associated with higher HDL cholesterol

4. The endogenous ligands for PPAR α and PPAR γ appear to include fatty acids. Fats from circulating lipoproteins may generate these ligands under the influence of:

a. lipoprotein lipase
b. hepatic lipase
c. cholesterol ester transport protein
d. all of the above

5. Circulating concentrations of the endogenous inhibitor of nitric oxide synthesis asymmetric dimethyl arginine (ADMA) are associated with CVD. ADMA levels may NOT be reduced by treatment with:

a. an inhibitor of the renin-angiotensin system
b. a thiazolidinedione
c. aspirin
d. a statin

6. There is evidence that insulin sensitivity may be improved with all of the following EXCEPT:

a. sustained weight loss
b. a thiazolidinedione
c. a statin
d. metformin

7. In the Diabetes REduction Assessment with rampril and rosiglitazone Medication (DREAM) Study, administration of ramipril led to:

a. reduction in development of diabetes
b. no glycemic benefit
c. weight loss and protection against rosiglitazone-induced edema
d. reduction in post-load glucose levels

8. In the DREAM study, administration of rosiglitazone led to:

a. reduction in development of diabetes
b. no glycemic benefit
c. weight loss
d. reduction in CVD development